JP7689125B2 - ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体 - Google Patents

ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体 Download PDF

Info

Publication number
JP7689125B2
JP7689125B2 JP2022534761A JP2022534761A JP7689125B2 JP 7689125 B2 JP7689125 B2 JP 7689125B2 JP 2022534761 A JP2022534761 A JP 2022534761A JP 2022534761 A JP2022534761 A JP 2022534761A JP 7689125 B2 JP7689125 B2 JP 7689125B2
Authority
JP
Japan
Prior art keywords
seq
human
antibody
cdr
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507280A5 (cg-RX-API-DMAC7.html
JP2023507280A (ja
Inventor
ラーマン カーン、アドナン
フィリップ ヘイウッド、サム
ポール ハンフリーズ、デイヴィッド
ジョン ライトウッド、ダニエル
デイブ、エマ
メアリー ケアリスティン バリー、エミリー
ジェイン スタンヨン、セアラ
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2023507280A publication Critical patent/JP2023507280A/ja
Publication of JP2023507280A5 publication Critical patent/JP2023507280A5/ja
Application granted granted Critical
Publication of JP7689125B2 publication Critical patent/JP7689125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022534761A 2019-12-20 2020-12-18 ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体 Active JP7689125B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1919061.0A GB201919061D0 (en) 2019-12-20 2019-12-20 Multi-specific antibody
GB1919061.0 2019-12-20
PCT/EP2020/087046 WO2021123186A1 (en) 2019-12-20 2020-12-18 Multi-specific antibody with binding specificity for human il-13 and il-17

Publications (3)

Publication Number Publication Date
JP2023507280A JP2023507280A (ja) 2023-02-22
JP2023507280A5 JP2023507280A5 (cg-RX-API-DMAC7.html) 2023-12-06
JP7689125B2 true JP7689125B2 (ja) 2025-06-05

Family

ID=69323008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534761A Active JP7689125B2 (ja) 2019-12-20 2020-12-18 ヒトil-13及びil-17に対する結合特異性を有する多重特異性抗体

Country Status (19)

Country Link
US (2) US12570738B2 (cg-RX-API-DMAC7.html)
EP (1) EP4077381A1 (cg-RX-API-DMAC7.html)
JP (1) JP7689125B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220117307A (cg-RX-API-DMAC7.html)
CN (3) CN122541578A (cg-RX-API-DMAC7.html)
AR (1) AR120818A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020407279A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011627A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164276A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001685A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009711A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22054471A (cg-RX-API-DMAC7.html)
GB (1) GB201919061D0 (cg-RX-API-DMAC7.html)
IL (1) IL294035A (cg-RX-API-DMAC7.html)
MX (1) MX2022007150A (cg-RX-API-DMAC7.html)
PE (1) PE20221173A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551411A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021123186A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207715B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US20240067758A1 (en) * 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
TW202613165A (zh) 2024-05-17 2026-04-01 比利時商Ucb生物製藥公司 具有il-11和il-17結合特異性的多特異性抗體

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505474A (ja) 2011-01-14 2014-03-06 ユセベ ファルマ ソシエテ アノニム Il−17aとil−17fに結合する抗体分子
JP2014534978A (ja) 2011-11-11 2014-12-25 ユセベ ファルマ ソシエテ アノニム アルブミン結合抗体及びその結合断片
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE19653722C2 (de) 1996-12-10 2000-06-29 Brose Fahrzeugteile Beidseitig wirkende Verstellvorrichtung
CA2281794A1 (en) 1997-02-21 1998-08-27 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004051268A1 (en) 2002-12-03 2004-06-17 Celltech R & D Limited Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
WO2019220109A1 (en) * 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505474A (ja) 2011-01-14 2014-03-06 ユセベ ファルマ ソシエテ アノニム Il−17aとil−17fに結合する抗体分子
JP2014534978A (ja) 2011-11-11 2014-12-25 ユセベ ファルマ ソシエテ アノニム アルブミン結合抗体及びその結合断片
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用

Also Published As

Publication number Publication date
TW202130365A (zh) 2021-08-16
EP4077381A1 (en) 2022-10-26
IL294035A (en) 2022-08-01
BR112022011627A2 (pt) 2022-09-13
CN114846026B (zh) 2026-05-15
PH12022551411A1 (en) 2023-11-20
GB201919061D0 (en) 2020-02-05
CA3164276A1 (en) 2021-06-24
PE20221173A1 (es) 2022-07-25
US20230087378A1 (en) 2023-03-23
AU2020407279A1 (en) 2022-08-11
MX2022007150A (es) 2022-07-19
KR20220117307A (ko) 2022-08-23
US20260226151A1 (en) 2026-08-06
CO2022009711A2 (es) 2022-07-19
ZA202207715B (en) 2024-01-31
CL2022001685A1 (es) 2023-05-26
ECSP22054471A (es) 2022-08-31
US12570738B2 (en) 2026-03-10
CL2023002975A1 (es) 2024-04-01
WO2021123186A1 (en) 2021-06-24
CN122502498A (zh) 2026-08-04
CN114846026A (zh) 2022-08-02
CN122541578A (zh) 2026-08-11
JP2023507280A (ja) 2023-02-22
AR120818A1 (es) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6329516B2 (ja) Il−17a及びil−17fに結合する抗体分子
RU2747980C2 (ru) Молекулы со специфичностью к cd45 и cd79
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
BR112013017951B1 (pt) Anticorpo de neutralização, sequência de dna isolada, vetor de clonagem ou expressão, processo para a produção do anticorpo, composição farmacêutica, uso de anticorpo e uso da composição farmacêutica
US12570738B2 (en) Multi-specific antibody with binding specificity for human IL-13 and IL-17
JP7710446B2 (ja) ヒトil‐13に結合特異性を有する抗体
US11091542B2 (en) Antibody molecules which bind TNF alpha
US20230374148A1 (en) Binding molecules that multimerise cd45
RU2827946C1 (ru) Мультиспецифическое антитело со специфичностью связывания il-13 и il-17 человека
HK40069078A (en) Multi-specific antibody with binding specificity for human il-13 and il-17
HK40069079A (en) Antibody with binding specificity for human il-13.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250526

R150 Certificate of patent or registration of utility model

Ref document number: 7689125

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150